טוען...
Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
Inhibitors of sodium-glucose co-transporter type 2 (SGLT2), such as canagliflozin and dapagliflozin, are recently approved for treatment of type 2 diabetes. These agents lower blood glucose mainly by increasing urinary glucose excretion. Compared with placebo, SGLT2 inhibitors reduce hemoglobin A1c...
שמור ב:
| הוצא לאור ב: | World J Diabetes |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265871/ https://ncbi.nlm.nih.gov/pubmed/25512787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v5.i6.854 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|